$IQV

Patel Bhavik sold $436K of IQV

Patel Bhavik (See Remarks) sold 1,855 shares of IQVIA HOLDINGS INC. (IQV) at $235.27 ($0.44M total) on 2026-07-31.

Original reporting
SEC EDGAR · Patel Bhavik
Published Aug 4, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 4, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IQV
Neutral
medium confidence
Mentioned
$IQV
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IQVNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not introduce new operational, financial, or regulatory information about IQVIA.

02

Market read

Traders may note the insider sale for sentiment monitoring, but there is no direct fundamental catalyst in the text.

03

What to watch

Insider sales are often driven by taxes, diversification, or pre-existing compensation schedules; without stated purpose, the signal quality is low.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-04 after-hours; sale dated 2026-07-31

Background

The article is a SEC Form 4 insider transaction disclosure for IQVIA Holdings Inc.

Company-level read

Ticker impact

$IQVNeutralMedium confidence
Context

IQVIA Form 4 shows officer Patel Bhavik sold 1,855 shares on 2026-07-31 at $235.27 for about $436.4K.

Expected impact

Likely limited near-term impact; any effect would be brief and sentiment-driven rather than a fundamental repricing.

Evidence & confidence

The filing discloses transaction size and price but provides no new company performance, guidance, or regulatory/legal catalyst. Insider sales can be non-informational, and the article lacks additional context (e.g., compensation, tax, diversification).

Market effects

Minimal; insider-sale disclosures rarely change sector fundamentals for healthcare services/pharma services.

None indicated.

None indicated.

Counterpoint

Absence of a 10b5-1 plan could be interpreted by some traders as potentially more informative than typical planned sales, even though the article provides no rationale.

Key entities

  • IQVIA HOLDINGS INC.

    Subject of the Form 4 insider transaction disclosure.

  • Patel Bhavik

    Officer who sold 1,855 shares in an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IQVHighAI 8/10

IQVIA Holdings (IQV) Prices $2b In Senior Notes, Is The Stock Still Undervalued?

IQVIA Holdings (IQV) priced a $2b senior notes offering due 2034. The company's share price has surged 58.8% in 90 days, with a 1-year return of 42.3%. Analysts estimate a fair value of $275.17, suggesting a modest undervaluation. However, risks include contract pricing pressure and higher leverage. The company's R&D solutions backlog and pipeline growth indicate sustained demand.

$IQVMed

Learn Why The Bull Case For IQVIA (IQV) Could Change Following AI Trial Platform Launch

IQVIA Holdings priced a $2.0b senior notes offering due 2034 to refinance debt and cover costs. The company launched IQVIA Predictive Clinical Development, an AI-driven platform aimed at accelerating clinical trials. Analysts project revenues of $20.4b and earnings of $2.0b by 2029, but debt remains a key risk. The AI platform could enhance growth and defend pricing power, though competition from in-house pharma tools is a concern.

$IQVHighAI 8/10

IQVIA stock rises amid $2 billion senior notes offering

IQVIA Holdings Inc. (IQV) shares rose 4.3% after announcing a $2 billion senior notes offering due 2034, with a 6.375% interest rate. Proceeds will redeem existing notes, repay debt, and cover offering fees. The offering is expected to close by September 23, 2026, and is targeted at institutional buyers and non-U.S. investors. IQVIA is a global provider of clinical research and healthcare intelligence services.